POA Pharma Scandinavia AB, a subsidiary of Galen Limited, has entered into a new licensing partnership with Istituto Gentili, under which POA Pharma Scandinavia will assume exclusive distribution responsibilities across Denmark, Finland and Norway.

The agreement represents a further step in POA Pharma’s continued expansion across the Nordic region and reinforces the company’s commitment to improving access to established, high‑quality therapies. The partnership covers a medication used in paediatric care, with POA Pharma’s well‑established Nordic infrastructure supporting a smooth transition and ensuring continuity of supply for healthcare professionals.

With a strong regional presence and proven commercial capabilities, POA Pharma Scandinavia is well positioned to maintain stability within existing supply chains while continuing to support clinicians and patients across the region.

Commenting on the partnership, Johnny McGaughey, Head of Business Development at Galen, said:

“We are delighted to partner with Istituto Gentili as part of our ongoing investment in the Nordic region. Their commitment to high‑quality, patient‑focused solutions aligns closely with our own values, and we look forward to combining our strengths to deliver meaningful impact across the Nordic markets.”

Alessandro Del Bono, CEO of Istituto Gentili, added:

“This partnership marks a significant step forward in our commitment to delivering high‑quality therapeutic solutions to patients and healthcare professionals. By partnering with Galen and POA Pharma Scandinavia, we are strengthening our presence in the Nordic region, ensuring continuity of access and supporting the effective and appropriate management of paediatric patients. We are proud to collaborate with a trusted international partner to enhance quality of care and improve patient outcomes.”

The collaboration underscores POA Pharma’s strategy of working with like‑minded partners to expand its licensing portfolio and deliver specialist medicines to Nordic healthcare systems.